The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of ABR in pts with TN or R/R MCL: Ph Ib trial.
 
Tycel Jovelle Phillips
Honoraria - Lymphoma & Myeloma Connect; Seagen
Consulting or Advisory Role - ADC Therapeutics; Bayer; Celgene; Curis; Genentech; Genmab; Gilead Sciences; Incyte; Kite/Gilead; Lilly; Pharmacyclics; Seagen; TG Therapeutics
Research Funding - Abbvie; Bayer; Genentech; Pharmacyclics/Janssen
 
Michael Wang
Honoraria - Abbvie; Acerta Pharma; AstraZeneca; Bantam Pharmaceutical; BeiGene; Bioinvent; Breast-Gynecological International Cancer Society; Bristol Myers Squibb Foundation; CAHON; Dava Oncology; Eastern Virginia Medical School; Genmab; IDEOlogy Health; Janssen Research & Development; Kite, a Gilead company; Leukemia and Lymphoma Society; MD Education; Medscape; Meeting Minds Experts; Merck; Moffit Cancer Center; Nurix; OncLive/MJH Life Sciences; Oncology Specialty Group; Pharmacyclics/Janssen; Physicans' Education Resource; Practice Point Communications; Studio ER Congressi
Consulting or Advisory Role - Abbvie; Acerta Pharma; ADC Therapeutics; Amphista Therapeutics; AstraZeneca; Be Biopharma; BeiGene; Bioinvent; Deciphera; DTRM; Genentech; Innocare; Janssen Research & Development; Kite, a Gilead company; Leukemia and Lymphoma Society; Lilly; Merck; Milken Institute; Miltenyi Biomedicine; Oncternal Therapeutics; Parexel; Pepromene; Pepromene; Pharmacyclics/Janssen; VelosBio
Research Funding - Acerta Pharma; AstraZeneca; BeiGene; Bioinvent; Celgene; Genentech; Genmab; Innocare; Janssen Research & Development; Juno Therapeutics; Kite, a Gilead company; Lilly; Loxo; Molecular Templates; Oncternal Therapeutics; Pharmacyclics; VelosBio; Vincerx Pharma
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Dava Oncology; Kite, a Gilead company; Physicans' Education Resource
 
Tadeusz Robak
Honoraria - AstraZeneca; BeiGene; Janssen
Consulting or Advisory Role - AstraZeneca; BeiGene; Janssen Oncology
Research Funding - AstraZeneca; BeiGene; Janssen
 
David Gallinson
No Relationships to Disclose
 
Don A. Stevens
No Relationships to Disclose
 
Krish Patel
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene/Juno; Epizyme; Genentech; Kite, a Gilead company; Loxo/Lilly; Morphosys; Pharmacyclics; Seagen; TG Therapeutics
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb/Celgene; Kite, a Gilead company; TG Therapeutics
Research Funding - Aptevo Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Curis (Inst); Epizyme (Inst); Fate Therapeutics (Inst); Kite/Gilead (Inst); Loxo/Lilly (Inst); MEI Pharma (Inst); Nurix (Inst); Pharmacyclics (Inst); Roche/Genentech (Inst); Takeda (Inst); Trillium Therapeutics (Inst); Xencor (Inst)
 
Safaa Ramadan
Employment - AstraZeneca
 
Chuan-Chuan Wun
Employment - AstraZeneca
 
Wojciech Jurczak
Consulting or Advisory Role - AstraZeneca; BeiGene; Roche
Research Funding - Acerta Pharma; BeiGene; Epizyme; Janssen-Cilag; MEI Pharma; Morphosys; Roche; Sandoz-Novartis; Takeda; TG Therapeutics; TG Therapeutics
 
Stephen Douglas Smith
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BeiGene; Coherus Biosciences (I); Epizyme; Incyte; Karyopharm Therapeutics; Kite, a Gilead company; Numab
Research Funding - Acerta Pharma/AstraZeneca (Inst); ADC Therapeutics (Inst); Ayala Pharmaceuticals (I); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (I); Denovo Biopharma (Inst); Enterome (Inst); Genentech (Inst); Ignyta (I); Incyte (Inst); Kymera (Inst); Merck (Inst); MorphoSys/Incyte (Inst); Nanjing (Inst); Portola Pharmaceuticals (Inst); Portola Pharmaceuticals/Alexion Pharmaceuticals (Inst); Viracta Therapeutics (Inst)